Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

Trial Profile

Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Darbepoetin alfa (Primary)
  • Indications Anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms START-CKD
  • Sponsors Amgen
  • Most Recent Events

    • 24 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 07 Mar 2016 Planned End Date changed from 1 Mar 2018 to 1 Oct 2017, reported by ClinicalTrials.gov record.
    • 15 Feb 2016 Planned primary completion date changed from 1 Mar 2018 to 1 Oct 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top